Floatz logo

Dcb-Bo1202+

HEPATITIS B CHRONIC

A2 Healthcare Taiwan CorporationPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the HEPATITIS B CHRONIC cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
TENOFOVIR DISOPROXIL FUMARATE
Ningbo No.2 Hospital
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
Adefovir Dipivoxil
Asian-Pacific Alliance of Liver Disease, Beijing
Phase 4BB

View all 29 →

Same molecule, other indications

Dcb-Bo1202+ is also rated in:

fibrotic liver diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →